blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP0711168

EP0711168 - METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS [Right-click to bookmark this link]
StatusThe application is deemed to be withdrawn
Status updated on  17.07.1998
Database last updated on 11.09.2024
Most recent event   Tooltip17.07.1998Application deemed to be withdrawnpublished on 02.09.1998 [1998/36]
Applicant(s)For all designated states
LXR BIOTECHNOLOGY INC.
1401 Marina Way South
Richmond, CA 94804 / US
[1996/20]
Inventor(s)01 / TOMEI, L., David
27 Seabreeze Dr. , Marine Bay
Richmond, CA 94804 / US
[1996/20]
Representative(s)Goldin, Douglas Michael
J.A. KEMP & CO. 14 South Square Gray's Inn
London WC1R 5JJ / GB
[N/P]
Former [1996/20]Goldin, Douglas Michael
J.A. KEMP & CO. 14, South Square Gray's Inn
London WC1R 5LX / GB
Application number, filing date94922680.722.07.1994
[1996/20]
WO1994US08268
Priority number, dateUS1993009678823.07.1993         Original published format: US 96788
[1996/20]
Filing languageEN
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO9503054
Date:02.02.1995
Language:EN
[1995/06]
Type: A1 Application with search report 
No.:EP0711168
Date:15.05.1996
Language:EN
The application published by WIPO in one of the EPO official languages on 02.02.1995 takes the place of the publication of the European patent application.
[1996/20]
Search report(s)International search report - published on:US02.02.1995
(Supplementary) European search report - dispatched on:EP16.02.1998
ClassificationIPC:A61K31/495, A61K31/44
[1996/20]
CPC:
A61K31/495 (EP,KR); A61P13/02 (EP); A61P15/00 (EP);
A61P17/00 (EP); A61P25/00 (EP); A61P31/12 (EP);
A61P35/00 (EP); A61P37/00 (EP); A61P43/00 (EP);
Y02A50/30 (EP) (-)
Designated contracting statesAT,   BE,   CH,   DE,   DK,   ES,   FR,   GB,   GR,   IE,   IT,   LI,   LU,   MC,   NL,   PT,   SE [1996/20]
TitleGerman:VERFAHREN ZUR BEHANDLUNG VPN APOPTOSE UND DAMIT VERBUNDENEN ZUSTAENDEN[1996/20]
English:METHODS OF TREATING APOPTOSIS AND ASSOCIATED CONDITIONS[1996/20]
French:PROCEDES DE TRAITEMENT DE L'APOPTOSE ET D'ETATS ASSOCIES[1996/20]
Entry into regional phase14.02.1996National basic fee paid 
14.02.1996Search fee paid 
14.02.1996Designation fee(s) paid 
14.02.1996Examination fee paid 
Examination procedure22.02.1995Request for preliminary examination filed
International Preliminary Examining Authority: US
14.02.1996Examination requested  [1996/20]
24.03.1998Despatch of communication that the application is deemed to be withdrawn, reason: renewal fee not paid in time  [1998/36]
26.04.1998Application deemed to be withdrawn, date of legal effect  [1998/36]
Fees paidRenewal fee
17.07.1996Renewal fee patent year 03
Penalty fee
Additional fee for renewal fee
31.07.199704   M06   Not yet paid
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[X]WO9208460  (WINDLESHAW ENTERPRISES LTD [GB]) [X] 1-3,10,11 * the whole document *;
 [X]  - TANABE ET AL., "Inhibition of Topoisomerase II by Antitumor Agents Bis(2,6-dioxopiperazine) Derivatives", CANCER RESEARCH, (1991), vol. 51, pages 4903 - 4908, XP002046914 [X] 1,10 * the whole document *
 [X]  - SEHESTED ET AL., "ANTAGONISTIC EFFECT OF THE CARDIOPROTECTOR (+)-1,2-BIS(3,5-DIOXOPIPERAZINYL-1-YL)PROPANE (ICRF-187) ON DNA BREAKS AND CYTOTOXICITY INDUCED BY THE TOPOISOMERASE II DIRECTED DRUGS DAUNORUBICIN AND ETOPOSIDE (VP-16)", BIOCHEMICAL PHARMACOL., (1993), vol. 46, no. 3, pages 389 - 393, XP002046915 [X] 1-5,10,11 * the whole document *

DOI:   http://dx.doi.org/10.1016/0006-2952(93)90514-W
 [X]  - CHACHOUA ET AL., "Phase II trial of ICRF-187 in patients with acquired immune deficiency related Kaposi's Sarcoma (AIDS-KS)", INVEST. NEW DRUGS, (1989), vol. 7, no. 4, pages 327 - 332, XP002046916 [X] 1-4,10,11 * the whole document *

DOI:   http://dx.doi.org/10.1007/BF00173762
 [X]  - HELLMAN K., "Effect of ICRF 159 on Immune Responses.", PROC. ROY. SOC. MED., (1972), vol. 65, no. 3, pages 264 - 265, XP002046917 [X] 1-3,10 * the whole document *
 [X]  - DUKE ET AL., "Immunosuppression by the Bisdioxopiperazines ICRF 154 and 159", BIOMEDICINE, (1973), vol. 18, no. 3, pages 199 - 205, XP002046918 [X] 1-3,10 * the whole document *
 [X]  - HAUG ET AL., "Simultaneous assessment of migration and proliferation of murine fibrosarcoma cells, as affected by hydroxyurea, vinblastine, cytochalasin B, razoxane and interferon.", CELL PROLIFERATION, vol. 26, no. 3, pages 251 - 261, XP002046919 [X] 1-3,10 * the whole document *
 [X]  - BU'LOCK ET AL., "Cardioprotection by ICRF187 against high dose anthracycline toxicity in children with malignant disease", BRITISH HEART JOURNAL, (1993), vol. 70, no. 2, pages 185 - 188, XP002046920 [X] 1-3,5,6,10,11 * the whole document *
 [X]  - HERMAN ET AL., "Protective Effect of ICRF-187 on Doxorubicin-Induced Cardiac and Renal Toxicity in Spontaneously Hypertensive (SHR) and Normotensive (WKY) Rats", TOXICOL. APPL. PHARMACOL., (1988), vol. 92, no. 1, pages 42 - 53, XP002046921 [X] 1-3,5,10,11 * the whole document *

DOI:   http://dx.doi.org/10.1016/0041-008X(88)90226-8
 [X]  - HERMAN ET AL., "Timing of treatment with ICRF-187 and its effect on chronic doxorubicin cardiotoxicity.", CANCER CHEMOTHER. PHARMACOL., (1993), vol. 32, no. 6, pages 445 - 449, XP002046922 [X] 1-3,10,11 * the whole document *

DOI:   http://dx.doi.org/10.1007/BF00685888
 [X]  - HERMANN ET AL., "Examination of the potential long-lasting protective effect of ICRF-187 against anthracycline-induced chronic cardiomyopathy", CANCER TREAT. REVIEWS, (1990), vol. 17, no. 2-3, pages 155 - 160, XP002046923 [X] 1-3,10,11 * the whole document *

DOI:   http://dx.doi.org/10.1016/0305-7372(90)90040-M
 [PX]  - ONISHI ET AL., "BIS(2,6-DIOXOPIPERAXINE) DERIVATIVES, TOPOISOMERASE ii INHIBITORS WHICH DO NOT FORM A DNA CLEAVABLE COMPLEX, INDUCE THYMOCYTE APOPTOSIS", BIOCHEM. MOL. BIOL. INT., (1994), vol. 32, no. 1, pages 115 - 122, XP002046924 [PX] 1,2,10 * the whole document *
International search[X]WO9100729  (NAT RES DEV [GB])
 [X]  - ONCOLOGY, Volume 6, No. 6, issued June 1992, (California, US), R.W. CARLSON: "Reducing the Cardiotoxicity of the Anthracyclines", pages 95-100, see the entire document.
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.